UNSPSC 51361501: Chloral hydrate

This classification denotes an adjuvant analgesic with the molecular formula C2H3Cl3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418M5916WG, chemically known as 2,2,2-trichloroethane-1,1-diol but generally known as chloral hydrate, which bears US NIH Compound Identifier 2707. European Medicines Agency schedules Chloral hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13324MIG. World Health Organization schedules chloral hydrate in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, CHLORAL HYDRATE remains the US FDA Preferred Term for this commodity. Chloral hydrate bears US NLM identifiers UMLS ID C0008161 and NCI Concept Code C28922. SMILES: C(C(Cl)(Cl)Cl)(O)O.

UNSPSC 51361501 Chloral hydrate is a Commodity code that nominally covers pharmaceutical sedatives, but recent state and local procurement activity under this code shows a significant mismatch: the sole recent opportunity tagged to it concerns naloxone (an opioid-reversal agent) and drug deactivation systems, which fall outside the code's stated scope. State and local governments do not appear to be actively soliciting chloral hydrate through standard procurement channels at present. The posted opportunity does not reflect procurement of the chloral hydrate product the code nominally describes.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through electronic bidding via the county's e-Procurement Portal. The solicitation requires quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping costs. Bidders must meet E-Verify compliance, drug-free workplace certification, and insurance requirements including workers' compensation and commercial general liability. The contract carries an initial two-year term with a one-year renewal option and a three-month probationary period. The misalignment between the code assignment and the actual procurement suggests either a data-entry error in the source system or that this code is not in active use for state and local pharmaceutical procurement. No other recent opportunities appear in the source under this code.